Mutual of America Capital Management LLC Sells 5,110 Shares of Illumina, Inc. (NASDAQ:ILMN)

Mutual of America Capital Management LLC lowered its stake in Illumina, Inc. (NASDAQ:ILMN) by 5.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 86,095 shares of the life sciences company’s stock after selling 5,110 shares during the period. Mutual of America Capital Management LLC owned approximately 0.05% of Illumina worth $11,228,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. Cetera Advisors LLC bought a new stake in Illumina during the first quarter worth $610,000. Freemont Management S.A. bought a new stake in shares of Illumina during the 3rd quarter worth $1,565,000. Weybosset Research & Management LLC boosted its stake in Illumina by 92.0% in the third quarter. Weybosset Research & Management LLC now owns 18,052 shares of the life sciences company’s stock valued at $2,354,000 after buying an additional 8,650 shares in the last quarter. Bleakley Financial Group LLC bought a new position in Illumina in the first quarter valued at about $207,000. Finally, B. Riley Wealth Advisors Inc. raised its stake in Illumina by 176.3% during the second quarter. B. Riley Wealth Advisors Inc. now owns 7,176 shares of the life sciences company’s stock worth $749,000 after acquiring an additional 4,579 shares in the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Analysts Set New Price Targets

ILMN has been the topic of several research reports. Argus raised shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target on the stock in a report on Wednesday, August 28th. StockNews.com started coverage on shares of Illumina in a report on Thursday, August 29th. They set a “buy” rating for the company. Daiwa America raised Illumina to a “strong-buy” rating in a report on Friday, August 16th. Robert W. Baird upped their target price on Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Finally, Canaccord Genuity Group lifted their price target on Illumina from $130.00 to $145.00 and gave the company a “hold” rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Illumina currently has an average rating of “Moderate Buy” and an average target price of $164.00.

Illumina Trading Down 5.1 %

NASDAQ ILMN opened at $135.05 on Monday. The stock has a market capitalization of $21.42 billion, a P/E ratio of -13.56 and a beta of 1.13. The business has a 50 day simple moving average of $139.66 and a 200 day simple moving average of $124.31. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a one year low of $92.69 and a one year high of $156.66.

Illumina (NASDAQ:ILMN) last released its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to analyst estimates of $1.08 billion. During the same quarter in the previous year, the business posted $0.33 EPS. Illumina’s revenue for the quarter was down 3.5% compared to the same quarter last year. Research analysts expect that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.